Quick Answer
Sigyn Therapeutics, Inc. reported Earnings Per Share Diluted of $2.51 (loss) per share for the year ending 2024.
- Sigyn Therapeutics, Inc. showed an increase of +33.4% in Earnings Per Share Diluted from 2023 to 2024.
- This data is from Sigyn Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2022 to 2024 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $0.02 (loss) per share | Q3 2022: $0.02 (loss) per share | Q1 2023: $1.39 (loss) per share | Q2 2023: $0.67 (loss) per share | Q3 2023: $0.82 (loss) per share | Q1 2024: $0.62 (loss) per share | Q2 2024: $0.70 (loss) per share | Q3 2024: $0.94 (loss) per share | Q1 2025: $0.42 (loss) per share | Q2 2025: $0.90 (loss) per share | Q3 2025: $0.36 (loss) per share.
- Over the full 3 years of available data (2022 to 2024), Sigyn Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 19.8%.
- Historical annual values: Fiscal year 2024: $2.51 (loss) per share | Fiscal year 2023: $3.77 (loss) per share | Fiscal year 2022: $3.13 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: